Numerate, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Numerate, Inc. - overview
Established
2007
Location
San Francisco, CA, US
Primary Industry
Pharmaceuticals
About
Based in California, US, and founded in 2007 by CEO Guido Lanza, Numerate, Inc. operates as a developer of an AI-based drug engineering platform that is used to design and develop small-molecule therapeutics for accelerating immuno-oncology, regenerative medicine, and the treatment of various diseases like Alzheimer’s and metabolic diseases. In November 2019, Valo Health, Inc. , a portfolio company of Koch Disruptive Technologies, Longevity Vision Holding, Mirae Asset Capital, Atinum Investment, Invus, HBM Partners, Public Sector Pension Investment Board, and Flagship Pioneering, acquired Numerate, Inc.
from Foundation Capital, Lanza Tech Ventures, Atlas Venture, Lilly Ventures, and The National Heart, Lung, and Blood Institute. Numerate, Inc. developed a cloud-based AI platform designed for small-molecule drug discovery. This platform enabled data-driven decisions throughout the drug development lifecycle, from hit identification to lead optimization and candidate selection.
It was capable of modeling biological systems with limited, noisy, or biased data and featured predictive models for ADME/Tox and protein target interaction. The company focuses on various therapeutic areas such as neurodegeneration, oncology, and cardiovascular disease, supporting both internal programs and strategic external collaborations.
Current Investors
Foundation Capital, Lanza Tech Ventures, Valo Health, Inc.
Primary Industry
Pharmaceuticals
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Pharmaceutical Research & Development
Verticals
Artificial Intelligence, Big Data, HealthTech
Company Stage
Add-on
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.